Cyberonics Reiterates No Interest in Any Merger or Combination With Advanced Neuromodulation Systems
2004年9月16日 - 4:50AM
PRニュース・ワイアー (英語)
Cyberonics Reiterates No Interest in Any Merger or Combination With
Advanced Neuromodulation Systems Conference Call at 4:30 PM EDT
Today, September 15 HOUSTON, Sept. 15 /PRNewswire-FirstCall/ --
Cyberonics, Inc. (NASDAQ:CYBX) today announced that its Board of
Directors, after consulting with its financial advisor, Merrill
Lynch & Co., has unanimously rejected Advanced Neuromodulation
Systems Inc.'s (NASDAQ:ANSI) invitation to "meet to discuss a
business combination." The Company reconfirms its previously stated
position in its press release dated August 20, 2004, that it is not
interested in any combination or merger and remains focused on
strengthening its epilepsy business and gaining clarity and
certainty in a revised depression regulatory plan and timeline.
CONFERENCE CALL ACCESS INFORMATION A conference call to discuss
this press release will be held at 4:30 PM EDT today, Wednesday,
September 15, 2004. To listen to the conference call live by
telephone dial 877-451-8943 (if dialing from within the U.S.) or
706-679-3062 (if dialing from outside the U.S.). The conference ID
is 210644; the leader is Pam Westbrook. A replay of the conference
call will be available two hours after the completion of the
conference call on Wednesday, September 15, 2004 through Wednesday,
September 29, 2004 by dialing 800-642-1687 (if dialing from within
the U.S.) or 706-645-9291 (if dialing outside the U.S.). The replay
conference ID access code is 210644. ABOUT VNS THERAPY AND
CYBERONICS Cyberonics, Inc. was founded in 1987 to design, develop
and market medical devices for the long-term treatment of epilepsy
and other chronic neurological disorders using a unique therapy,
vagus nerve stimulation (VNS). Stimulation is delivered by the VNS
Therapy System, an implantable generator similar to a cardiac
pacemaker. The VNS Therapy System delivers preprogrammed
intermittent mild electrical pulses to the vagus nerve 24 hours a
day. The Company's initial market is epilepsy, which is
characterized by recurrent seizures. Epilepsy is the second most
prevalent neurological disorder. The Cyberonics VNS Therapy System
was approved by the FDA on July 16, 1997 for use as an adjunctive
therapy in reducing the frequency of seizures in adults and
adolescents over 12 years of age with partial onset seizures that
are refractory to antiepileptic medications. The VNS Therapy System
is also approved for sale as a treatment for epilepsy in all the
member countries of the European Economic Area, Canada, Australia
and other markets. To date, more than 27,000 epilepsy patients in
24 countries have accumulated over 79,000 patient years of
experience using VNS Therapy. The VNS Therapy System is approved
for sale in the European Economic Area and in Canada as a treatment
for depression in patients with treatment-resistant or treatment-
intolerant major depressive episodes including unipolar depression
and bipolar disorder (manic depression). VNS Therapy is at various
levels of investigational clinical study as a potential treatment
for depression, anxiety disorders, Alzheimer's disease, and chronic
headache/migraine. The Company is headquartered in Houston, Texas
and has an office in Brussels, Belgium. For additional information
please visit us at http://www.cyberonics.com/ . DATASOURCE:
Cyberonics, Inc. CONTACT: Pamela B. Westbrook, Vice President of
Finance and CFO of Cyberonics, Inc., +1-281-228-7200, or fax,
+1-281-218-9332, or ; or Helen Shik, Vice President of Schwartz
Communications, +1-781-684-0770 ext. 6587, or fax, +1-781-684-6500,
or , for Cyberonics, Inc. Web site: http://www.cyberonics.com/
Copyright
Advanced Neuromodulation (NASDAQ:ANSI)
過去 株価チャート
から 5 2024 まで 6 2024
Advanced Neuromodulation (NASDAQ:ANSI)
過去 株価チャート
から 6 2023 まで 6 2024
Real-Time news about Advanced Neuromodulation Systems (MM) (ナスダック市場): 0 recent articles
その他のAdvanced Neuromodulation Systems (MM)ニュース記事